Login to Your Account

Other News To Note

Friday, November 30, 2012
• Epizyme Inc., of Cambridge, Mass., said preclinical data showed that treatment with EPZ-5676, an S-adenosyl methionine competitive DOT1L inhibitor, showed dose-dependent antitumor activity in a genetically defined rat model of MLL-rearranged leukemia, when given as a continuous infusion for 21 days, and resulted in complete tumor regression with the highest dose tested.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription